Open Access

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

  • Authors:
    • William K. Oh
    • David McDermott
    • Camillo Porta
    • Antonin Levy
    • Reza Elaidi
    • Florian Scotte
    • Robert Hawkins
    • Daniel Castellano
    • Joaquim Bellmunt
    • Sun Young Rha
    • Jong-Mu Sun
    • Paul Nathan
    • Bruce A. Feinberg
    • Jeffrey Scott
    • Ray McDermott
    • Jin-Hee Ahn
    • John Wagstaff
    • Yen-Hwa Chang
    • Yen-Chuan Ou
    • Paul Donnellan
    • Chao-Yuan Huang
    • John McCaffrey
    • Po-Hui Chiang
    • Cheng-Keng Chuang
    • Caroline Korves
    • Maureen P. Neary
    • Jose R. Diaz
    • Faisal Mehmud
    • Mei Sheng Duh
  • View Affiliations

  • Published online on: November 15, 2013     https://doi.org/10.3892/ijo.2013.2181
  • Pages: 5-16
  • Copyright: © Oh et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this study was to assess the treatment patterns and safety of sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, Europe and Asia. Medical records were abstracted at 18 community oncology clinics in the US and at 21 tertiary oncology centers in US, Europe and Asia for 883 patients ≥18 years who had histologically/cytologically confirmed diagnosis of advanced RCC and received sunitinib (n=631), sorafenib (n=207) or bevacizumab (n=45) as first‑line treatment. No prior treatment was permitted. Data were collected on all adverse events (AEs) and treatment modifications, including discontinuation, interruption and dose reduction. Treatment duration was estimated using Kaplan-Meier analysis. Demographics were similar across treatment groups and regions. Median treatment duration ranged from 6.1 to 10.7 months, 5.1 to 8.5 months and 7.5 to 9.8 months for sunitinib, sorafenib and bevacizumab patients, respectively. Grade 3/4 AEs were experienced by 26.0, 28.0 and 15.6% of sunitinib, sorafenib and bevacizumab patients, respectively. Treatment discontinuations occurred in 62.4 (Asia) to 63.1% (US) sunitinib, 68.8 (Asia) to 90.0% (Europe) sorafenib, and 66.7 (Asia) to 81.8% (US) bevacizumab patients. Globally, treatment modifications due to AEs occurred in 55.1, 54.2 and 50.0% sunitinib, sorafenib and bevacizumab patients, respectively. This study in a large, global cohort of advanced RCC patients found that angiogenesis inhibitors are associated with high rates of AEs and treatment modifications. Findings suggest an unmet need for more tolerable agents for RCC treatment.
View References

Related Articles

Journal Cover

2014-January
Volume 44 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Rha SY, et al: Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol 44: 5-16, 2014.
APA
Oh, W.K., McDermott, D., Porta, C., Levy, A., Elaidi, R., Scotte, F. ... Duh, M.S. (2014). Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. International Journal of Oncology, 44, 5-16. https://doi.org/10.3892/ijo.2013.2181
MLA
Oh, W. K., McDermott, D., Porta, C., Levy, A., Elaidi, R., Scotte, F., Hawkins, R., Castellano, D., Bellmunt, J., Rha, S. Y., Sun, J., Nathan, P., Feinberg, B. A., Scott, J., McDermott, R., Ahn, J., Wagstaff, J., Chang, Y., Ou, Y., Donnellan, P., Huang, C., McCaffrey, J., Chiang, P., Chuang, C., Korves, C., Neary, M. P., Diaz, J. R., Mehmud, F., Duh, M. S."Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review". International Journal of Oncology 44.1 (2014): 5-16.
Chicago
Oh, W. K., McDermott, D., Porta, C., Levy, A., Elaidi, R., Scotte, F., Hawkins, R., Castellano, D., Bellmunt, J., Rha, S. Y., Sun, J., Nathan, P., Feinberg, B. A., Scott, J., McDermott, R., Ahn, J., Wagstaff, J., Chang, Y., Ou, Y., Donnellan, P., Huang, C., McCaffrey, J., Chiang, P., Chuang, C., Korves, C., Neary, M. P., Diaz, J. R., Mehmud, F., Duh, M. S."Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review". International Journal of Oncology 44, no. 1 (2014): 5-16. https://doi.org/10.3892/ijo.2013.2181